Clinical Trials Logo

Clinical Trial Summary

A large proportion of Asian patients with HCC present with locally advanced or metastatic disease,at which point they are ineligible for curative treatments.Oxaliplatin plus fluorouracil/leucovorin intravenous infusion was proved effective in prolonging progression-free survival(PFS) than doxorubicin as palliative chemotherapy in patients with advanced HCC from Asia. Besides, hepatic arterial infusion chemotherapy (HAIC)is a widely used method for primary or metastasis liver tumor with high local tumor response. To our knowledge, there have not been any prospective studies to assess the safety and effecacy of HAIC using oxaliplatin plus fluorouracil/leucovorin for patients with locally advanced HCC.Thus,the purpose of this phase 2 study was to assess the safety and effecacy of HAIC using oxaliplatin plus fluorouracil/leucovorin for patients with locally advanced HCC.


Clinical Trial Description

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and much more common in male than in female. Each year, the number of patients with HCC in China alone contributes to about 50% of the total cases and deaths in the world. In men, poor prognosis makes HCC the second most frequent cause of cancer-related mortality in less developed countries. Locally advanced or metastatic disease is found in 60%-70% of HCC patients at the time diagnosed, with a median survival time of only 3-4 months due to unavailability of potentially curative therapies. Therefore, treatments that can control the progression and improve the prognosis of advanced HCC are under great need in sufficient liver reservation. Recently, an oral multi-tyrosine kinase inhibitor sorafenib, was reported to significantly prolong overall survival (OS) and delay disease progression in patients with advanced HCC. To date, sorafenib is still the only standard treatment for advanced HCC approved by FDA. However, low response rates, modest survival advantages, high-level heterogeneity of individual response and relatively high cost, such limitations of sorafenib prohibit its widespread use in advanced HCC and more alternative therapies are highly required at present.

In fact, for the past 30 years, researchers never stop searching for effective chemotherapeutic agents for HCC, and a wide spectrum of cytotoxic drugs have been reported by a variety of studies, including doxorubicin, gemcitabine, capecitabine, 5-fluorouracil (5-FU), cisplatin and so on. Unfortunately, low and heterogeneous responses and the well-known toxic effects caused by chemotherapy severely slowed down the pace of drug development for HCC. Until last year, based on a multicenter randomized clinical trial known as the EACH study, Qin et al. reported that FOLFOX4 (oxaliplatin [OXA], leucovorin [LV], 5-FU) regimen was associated with significant better OS than doxorubicin regimen (5.7 vs. 4.3 months; hazard ratio: 0.74; P = 0.03) in Chinese subgroup that accounted for 75% of the EACH study population. This study has provided proof to suggest that the FOLFOX4 regimen may become a potentially more efficacious alternative to doxorubicin in Chinese patients with advanced HCC.

However, systemic toxicity of chemotherapy and impaired liver function is still a concern that could not be neglected. Compared with systemic chemotherapy, hepatic arterial infusion chemotherapy (HAIC) can provide chemotherapeutic agents to liver at higher concentration with lower toxicity and has been reported favor results in patients with advanced HCC. Additionally, for patients who are not initially eligible for curative treatment, e.g., resection or liver transplantation, HAIC may down disease stage and offer them a chance to undergo such treatment which gives good long-term results. Though various agents such as 5-FU and cisplatin were studied with HAIC, by far, there have been no data about the use of more effective regimens FOLFOX4 in HAIC. Therefore, we carried out a multi-center, prospective trial to investigate the effect and safety of HAI combined with FOLFOX4 regimens in Chinese population with advanced HCC. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02436044
Study type Expanded Access
Source Sun Yat-sen University
Contact
Status Approved for marketing
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2